Immuno-oncology for B-cell lymphomas

다국어 초록 (Multilingual Abstract)

The goal of cancer immunotherapy is to restore and optimize the immune response against malignant clones through several stages, from recognition of tumor antigens to establishment of long-lived memory cell populations. Boosting the intrinsic anti-tumor immune responses of the patients’ own, several types of “active immunotherapies” have been tried in many types of malignancies, inspired by successful experiences of immune checkpoint inhibition even in Hodgkin lymphoma. However, in B-cell non-Hodgkin lymphomas, clinical usefulness of such “active immunotherapies” is relatively unsatisfactory considering the remarkable advances in “passive immunotherapy,” including CD19-targeting chimeric antigen receptor T-cell therapy. Understanding how tumor cells and immune cells interact and contribute to immune evasion processes in the tumor microenvironment (TME) is an important prerequisite for the successful restoration of anti-tumor immune responses. In this review, a recent understanding of the biology of the immune tumor microenvironment surrounding B-cell non-Hodgkin lymphomas will be introduced. In addition, novel therapeutic approaches targeting the immune microenvironment other than immune checkpoint blockade are discussed.

참고문헌 (Reference)

1 Malaponte G, "Tumor microenvironment in diffuse large B-cell lymphoma : matrixmetalloproteinases activation is mediated by osteopontin overexpression" 1863 : 483-489, 2016

2 Ma CS, "The origins, function, and regulation of T follicular helper cells" 209 : 1241-1253, 2012

3 Wei Y, "The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy" 129 : 3347-3360, 2019

4 Dunn GP, "The immunobiology of cancer immunosurveillance and immunoediting" 21 : 137-148, 2004

5 Farinha P, "The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation" 115 : 289-295, 2010

6 Chapuy B, "Targetable genetic features of primary testicular and primary central nervous system lymphomas" 127 : 869-881, 2016

7 Chen Z, "TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision" 51 : 840-855, 2019

8 Houot R, "T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy" 113 : 3546-3552, 2009

9 Lenz G, "Stromal gene signatures in large-B-cell lymphomas" 359 : 2313-2323, 2008

10 Mourcin F, "Stromal cell contribution to human follicular lymphoma pathogenesis" 3 : 280-, 2012

11 Zinzani PL, "Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma" 130 : 267-270, 2017

12 Vitolo U, "ROBUST : first report of phase III randomized study of lenalidomide/R-CHOP(R2-CHOP)vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma" 37 (37): 36-37, 2019

13 Chen R, "Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087" 134 : 1144-1153, 2019

14 de Visser KE, "Paradoxical roles of the immune system during cancer development" 6 : 24-37, 2006

15 Goodman A, "PD-1-PD-L1 immunecheckpoint blockade in B-cell lymphomas" 14 : 203-220, 2017

16 Kwon M, "PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGF inhibitors" 26 : 1644-1655, 2020

17 Armand P, "Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II CheckMate 205 trial" 36 : 1428-1439, 2018

18 Ramchandren R, "Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma : safety and efficacy in the phase II CheckMate 205study" 37 : 1997-2007, 2019

19 Dubois S, "Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities : a LYSA Study" 22 : 2919-2928, 2016

20 Schwaller J, "Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness" 109 : 331-338, 2007

21 Nie M, "Neutrophil extracellular traps induced by IL8 promote diffuse large B-cell lymphoma progression via the TLR9 signaling" 25 : 1867-1879, 2019

22 Epron G, "Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth : role of IL-15 and CD40L signaling" 26 : 139-148, 2012

23 Chapuy B, "Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes" 24 : 679-690, 2018

24 Wherry EJ, "Molecular and cellular insights into T cell exhaustion" 15 : 486-499, 2015

25 Kim YH, "Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma(MAVORIC) : an international, open-label, randomised, controlled phase 3 trial" 19 : 1192-1204, 2018

26 Menter T, "Mechanisms of immune evasion and immune modulation by lymphoma cells" 8 : 54-, 2018

27 Ruan J, "Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin’s lymphoma" 12 : 5622-5631, 2006

28 Muppidi JR, "Loss of signalling via G13in germinal centre B-cell-derived lymphoma" 516 : 254-258, 2014

29 Habermann TM, "Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma" 145 : 344-349, 2009

30 Wiernik PH, "Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma" 26 : 4952-4957, 2008

31 Voorzanger N, "Interleukin(IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors" 56 : 5499-5505, 1996

32 Herrera AF, "Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma" 131 : 1183-1194, 2018

33 Béguelin W, "IL10 receptor is a novel therapeutic target in DLBCLs" 29 : 1684-1694, 2015

34 Pandey S, "IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma" 129 : 2507-2518, 2017

35 Canioni D, "High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial" 26 : 440-446, 2008

36 de Charette M, "Hide or defend, the two strategies of lymphoma immune evasion : potential implications for immunotherapy" 103 : 1256-1268, 2018

37 Hanahan D, "Hallmarks of cancer : the next generation" 2011

38 Coelho V, "Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins" 107 : 18587-18592, 2010

39 Pasqualucci L, "Genetics of follicular lymphoma transformation" 6 : 130-140, 2014

40 Schmitz R, "Genetics and pathogenesis of diffuse large B-cell lymphoma" 378 : 1396-1407, 2018

41 Georgiou K, "Genetic basis of PD-L1overexpression in diffuse large B-cell lymphomas" 127 : 3026-3034, 2016

42 Glas AM, "Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma" 25 : 390-398, 2007

43 Gopal AK, "First-in-human study of utomilumab, a 4-1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas" 26 : 2524-2534, 2020

44 Lin W, "Fc-dependent expression of CD137 on human NK cells : insights into ‘‘agonistic’’ effects of anti-CD137 monoclonal antibodies" 112 : 699-707, 2008

45 Meirav K, "Extrafollicular PD1 and intrafollicular CD3 expression are associated with survival in follicular lymphoma" 17 : 645-649, 2017

46 Xue T, "EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression" 50 : 725-729, 2018

47 Rawal S, "Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment" 190 : 6681-6693, 2013

48 Cha Z, "Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway" 350 : 154-160, 2017

49 Amé-Thomas P, "Characterization of intratumoral follicular helper T cells in follicular lymphoma : role in the survival of malignant B cells" 26 : 1053-1063, 2012

50 Manfroi B, "CXCL-8/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL" 77 : 1097-1107, 2017

51 Gu-Trantien C, "CD4⁺ follicular helper T cell infiltration predicts breast cancer survival" 123 : 2873-2892, 2013

52 Sugiyama D, "Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans" 110 : 17945-17950, 2013

53 Tzankov A, "Angiogenesis in nodal B cell lymphomas : a high throughput study" 60 : 476-482, 2007

54 Witzig TE, "An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma" 22 : 1622-1627, 2011

55 Nowakowski GS, "Addition of lenalidomide to R-CHOP(R2CHOP)improves outcomes in newly diagnosed diffuse large B-cell lymphoma(DLBCL) : first report of ECOG-ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R-CHOP" 37 (37): 37-38, 2019

56 Chester C, "4-1BB agonism : adding the accelerator to cancer immunotherapy" 65 : 1243-1248, 2016